

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
November 13, 2018**

**ORDER GRANTING CONFIDENTIAL TREATMENT
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

Gilead Sciences, Inc.

File No. 0-19731 - CF#36807

Gilead Sciences, Inc. submitted an application under Rule 24b-2 requesting an extension of previous grants of confidential treatment for information it excluded from the Exhibits to Forms 10-Q filed on May 6, 2005, November 4, 2011, and November 5, 2014 and Form 10-K filed on February 25, 2014.

Based on representations by Gilead Sciences, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibits will not be released to the public for the time periods specified:

Exhibit	to Form	Filed on	Confidential Treatment Granted
10.1	10-Q	May 6, 2005	through December 31, 2022
10.83	10-Q	November 4, 2011	through December 31, 2022
10.84	10-Q	November 4, 2011	through December 31, 2022
10.85	10-Q	November 4, 2011	through December 31, 2022
10.86	10-Q	November 4, 2011	through December 31, 2022
10.89	10-Q	November 5, 2014	through December 31, 2022
10.87	10-K	February 25, 2014	through December 31, 2022

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Brent J. Fields
Secretary